Dr. med. Veronika Bahlinger

Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Institute of Pathology

Pure large nested variant of urothelial carcinoma (Lnuc) is the prototype of an fgfr3 mutated aggressive urothelial carcinoma with luminal-papillary phenotype (2020) Weyerer V, Eckstein M, Compérat E, Juette H, Gaisa NT, Allory Y, Stöhr R, et al. Journal article Evaluation of Potential Targeted Therapy and Molecular Subtype in Large Nested Variant of Urothelial Carcinoma (LNUC) (2020) Weyerer V, Eckstein M, Comperat E, Juette H, Gaisa N, Allory Y, Stoehr R, et al. Conference contribution Association of KRT20 and KRT5 with response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer (2020) Roghmann F, Reike M, Wirtz R, Kriegmair M, Erben P, Tully K, Weyerer V, et al. Conference contribution Smoking status and PD-L1 mRNA-expression as a predictor of response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer (2020) Reike M, Juette H, Wirtz R, Erben P, Tully K, Eckstein M, Weyerer V, et al. Conference contribution Immune Cell Gene Expression Signature is Associated with Improved Outcome in Muscle-Invasive Urothelial Bladder Cancer Patients Treated with Radical Cystectomy (2020) Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz RM, Pfannstiel C, Wullweber A, et al. Conference contribution Dual Functional States of R406W-Desmin Assembly Complexes Cause Cardiomyopathy with Severe Intercalated Disc Derangement in Humans and in Knock-In Mice (2020) Herrmann H, Cabet E, Chevalier NR, Moosmann J, Schultheis D, Haas J, Schowalter M, et al. Journal article Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma (2019) Weyerer V, Weisser R, Moskalev E, Haller F, Stöhr R, Eckstein M, Zinnall U, et al. Journal article Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial (2019) Jarczyk J, Wirtz R, Roghmann F, Juette H, Kriegmair MC, Worst TS, Sikic D, et al. Conference contribution Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting (2019) Roghmann F, Wirtz R, Jarczyk J, Kriegmair MC, Worst TS, Sikic D, Wach S, et al. Conference contribution Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods (2019) Weyerer V, Stöhr R, Juette H, Wirtz R, Eckstein M, Roghmann F, Breyer J, et al. Conference contribution